Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The endocannabinoid system in guarding against fear, anxiety and stress

  • Lutz, Beat
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Hillard, Cecilia J.
The endocannabinoid (eCB) system has emerged as a central integrator linking the perception of external and internal stimuli to distinct neurophysiological and behavioural outcomes (such as fear reaction, anxiety and stress-coping), thus allowing an organism to adapt to its changing environment. eCB signalling seems to determine the value of fear-evoking stimuli and to tune appropriate behavioural responses, which are essential for the organism's long-term viability, homeostasis and stress resilience; and dysregulation of eCB signalling can lead to psychiatric disorders. An understanding of the underlying neural cell populations and cellular processes enables the development of therapeutic strategies to mitigate behavioural maladaptation., B.L. was supported by the German Research Foundation (SFB TRR 58, CRC 1080 and FOR 926); G.M. by the Institut national de la santé et de la recherche médicale (INSERM), the European Commission Seventh Framework Programme (REPROBESITY, HEALTH-F2-2008-223713, PAINCAGE and HEALTH-2014-603191), the European Research Council (Endofood, ERC-2010-StG−260515, CannaPreg and ERC-2014-PoC-640923), the Fondation pour la Recherche Medicale (DRM20101220445), the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR Blanc NeuroNutriSens ANR-13-BSV4-0006 and BRAIN ANR-10-LABX-0043); R.M. by the grants SAF2014-59648P, RETICS-RTA#RD12/0028/0023, AGAUR#2014-SGR-1547 and Health-F2-2013-602891; and C.J.H. by the US National Institutes of Health grants DA038663, DA026996 and MH102838.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Srivastava, Raj Kamal
  • Cutando Ruiz, Laura, 1985-
  • Ortega Alvaro, Antonio
  • Ruehle, Sabine
  • Remmers, Floortje
  • Bindila, Laura
  • Bellochio, Luigi
  • Marsicano, Giovanni
  • Lutz, Beat
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Stressful events can generate emotional memories linked to the traumatic incident, but they also can impair the formation of nonemotional memories. Although the impact of stress on emotional memories is well studied, much less is known about the influence of the emotional state on the formation of nonemotional memories. We used the novel object-recognition task as a model of nonemotional memory in mice to investigate the underlying mechanism of the deleterious effect of stress on memory consolidation. Systemic, hippocampal, and peripheral blockade of cannabinoid type-1 (CB1) receptors abolished the stress-induced memory impairment. Genetic deletion and rescue of CB1 receptors in specific cell types revealed that the CB1 receptor population specifically in dopamine β-hydroxylase (DBH)-expressing cells is both necessary and sufficient for stress-induced impairment of memory consolidation, but CB1 receptors present in other neuronal populations are not involved. Strikingly, pharmacological manipulations in mice expressing CB1 receptors exclusively in DBH(+) cells revealed that both hippocampal and peripheral receptors mediate the impact of stress on memory consolidation. Thus, CB1 receptors on adrenergic and noradrenergic cells provide previously unrecognized cross-talk between central and peripheral mechanisms in the stress-dependent regulation of nonemotional memory consolidation, suggesting new potential avenues for the treatment of cognitive aspects on stress-related disorders., We acknowledge a predoctoral fellowship from the Spanish Ministry of Education and a postdoctoral fellowship from the Investments for the Future Programme, Initiative of Excellence Bordeaux, ANR-10-IDEX-03-02 (to A.B.-G.); a postdoctoral fellowship from the Marie Curie action Seventh Framework Programme for Research and Technological Development, FP7-PEOPLE-2013 (to A.B.-G.); the partial support by FRAXA Research Foundation (M.G.-G.); a European Molecular Biology Organization postdoctoral fellowship (to L. Bellocchio); grants from Ministerio de Ciencia e Innovación [BFU2012-33500 and BFU2015-68568P (to A.O.), and SAF2014-59648-P (to R.M.) (MINECO/FEDER, UE)]; Instituto de Salud Carlos III Grant RD06/0001/0001 (to R.M.); Generalitat de Catalunya Grant SGR-2014-1547 (to R.M.); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia (R.M.); the German Research Council DFG Grants FOR926 (Core Unit Endocannabinoid Measurements) (to B.L.), CRC-TRR58 (to B.L.), and CRC1080 (to B.L.); EU-FP7 Grant REPROBESITY, HEALTH-F2-2008-223713 (to B.L. and G.M.); PainCage Grant HEALTH-2013-INNOVATION-1-603191 (to G.M.); INSERM (G.M.); European Research Council Grant ENDOFOOD, ERC–2010–StG–260515 (to G.M.); Fondation pour la Recherche Medicale (G.M.); Region Aquitaine (G.M.); and LABEX BRAIN Grant ANR-10-LABX-43 (to G.M.)
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Cannabinoid Control of Olfactory Processes: The Where Matters

  • Terral, Geoffrey
  • Marsicano, Giovanni
  • Grandes Moreno, Pedro Rolando
  • Soria Gómez, Edgar
Olfaction has a direct influence on behavior and cognitive processes. There are different neuromodulatory systems in olfactory circuits that control the sensory information flowing through the rest of the brain. The presence of the cannabinoid type-1 (CB1) receptor, (the main cannabinoid receptor in the brain), has been shown for more than 20 years in different brain olfactory areas. However, only over the last decade have we started to know the specific cellular mechanisms that link cannabinoid signaling to olfactory processing and the control of behavior. In this review, we aim to summarize and discuss our current knowledge about the presence of CB1 receptors, and the function of the endocannabinoid system in the regulation of different olfactory brain circuits and related behaviors., This research was funded by Fondation pour la Recherche Médicale (FRM, FDT20170436845) (to G.T.); The Basque Government (ITI230-19), Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU; grant RD16/0017/0012), MINECO/FEDER, UE (SAF2015-65034-R) (to P.G.); EU–FP7 (PAINCAGE, HEALTH-603191), European Research Council (Endofood, ERC–2010–StG–260515; CannaPreg, ERC-2014-PoC-640923, Micabra) (to G.M.); Ikerbasque (The Basque Foundation for Science) and MINECO (Ministerio de Economía y Competitividad) PGC2018-093990-A-I00 (to E.S.-G.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bex3 dimerization regulates NGF-dependent neuronal survival and differentiation by enhancing trkA gene transcription

  • Calvo, Laura
  • Anta, Begoña
  • López-Benito, Saray
  • Martín-Rodriguez, Carlos
  • Pérez González, Pilar
  • Martín-Zanca, Dionisio
  • Arévalo, Juan Carlos
The development of the nervous system is a temporally and spatially coordinated process that relies on the proper regulation of the genes involved. Neurotrophins and their receptors are directly responsible for the survival and differentiation of sensory and sympathetic neurons; however, it is not fully understood how genes encoding Trk neurotrophin receptors are regulated. Here, we show that rat Bex3 protein specifically regulates TrkA expression by acting at the trkA gene promoter level. Bex3 dimerization and shuttling to the nucleus regulate the transcription of the trkA promoter under basal conditions and also enhance nerve growth factor (NGF)-mediated trkA promoter activation. Moreover, qChIP assays indicate that Bex3 associates with the trkA promoter within a 150 bp sequence, immediately upstream from the transcription start site, which is sufficient to mediate the effects of Bex3. Consequently, the downregulation of Bex3 using shRNA increases neuronal apoptosis in NGF-dependent sensory neurons deprived of NGF and compromises PC12 cell differentiation in response to NGF. Our results support an important role for Bex3 in the regulation of TrkA expression and in NGF-mediated functions through modulation of the trkA promoter., This work was supported by Ministerio de Ciencia e Innovación Grant BFU2008-00162, by Ministerio de Economía y Competitividad Grant (BFU2011-22898 to J.C.A. and BFU2013-39394-P to P.P.), by a Marie Curie International Reintegration Grant within the European Community 7th Framework Programme, by the Consejería de Educación Grant SA074A08, and by a Consejería de Sanidad de Junta Castilla y León grant to J.C.A. This work was in part supported by the FP7-PAINCAGE integrative project. D.M.-Z. is funded by a grant from the Spanish “Instituto de Saludo Carlos III” PI1202847. L.C. has been the recipient of a Predoctoral Fellowship from the University of Salamanca. J.C.A. was a “Ramón y Cajal” Investigator from the University of Salamanca and a NARSAD 2009 Young Investigator Awardee., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Regulation of BDNF release by ARMS/Kidins220 through modulation of synaptotagmin-IV levels

  • López-Benito, Saray
  • Sánchez-Sánchez, Julia
  • Brito, Verónica
  • Calvo, Laura
  • Lisa, Silvia
  • Torres-Valle, María
  • Palko,Mary E.
  • Vicente García, Cristina
  • Fernandez-Fernandez, Seila
  • Bolaños, Juan P.
  • Ginés, Silvia
  • Tessarollo, Lino
  • Arévalo, Juan Carlos
BDNF is a growth factor with important roles in the nervous system in both physiological and pathological conditions, but the mechanisms controlling its secretion are not completely understood. Here, we show that ARMS/Kidins220 negatively regulates BDNF secretion in neurons from the CNS and PNS. Downregulation of the ARMS/Kidins220 protein in the adult mouse brain increases regulated BDNF secretion, leading to its accumulation in the striatum. Interestingly, two mouse models of Huntington's disease (HD) showed increased levels of ARMS/Kidins220 in the hippocampus and regulated BDNF secretion deficits. Importantly, reduction of ARMS/Kidins220 in hippocampal slices from HD mice reversed the impaired regulated BDNF release. Moreover, there are increased levels of ARMS/Kidins220 in the hippocampus and PFC of patients with HD. ARMS/Kidins220 regulates Synaptotagmin-IV levels, which has been previously observed to modulate BDNF secretion. These data indicate that ARMS/Kidins220 controls the regulated secretion of BDNF and might play a crucial role in the pathogenesis of HD., This work was supported by MINECO BFU2011-22898, BFU2014-51846-R, and BFU2017-82667-R to J.C.A. and SAF2013-41177-RtoJ.P.B., andthe EU 7th Framework Program(Marie Curie IRG and PAINCAGE)toJ.C.A. S.L.-B.was supported by Consejería de Educacio´n Junta de Castilla y Leo´n and the European Social Fund. M.E.P. and L.T. were supported by the National Institutes of Health Intramural Research Program, Center for Cancer Research, National Cancer Institute., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ubiquitin-specific Protease 36 (USP36) Controls Neuronal Precursor Cell-expressed Developmentally Down-regulated 4-2 (Nedd4-2) Actions over the Neurotrophin Receptor TrkA and Potassium Voltage-gated Channels 7.2/3 (Kv7.2/3)

  • Anta, Begoña
  • Martín-Rodríguez, Carlos
  • Gomis-Perez, Carolina
  • Calvo, Laura
  • López-Benito, Saray
  • Calderón-García, Andrés A.
  • Vicente-García, Cristina
  • Villarroel, Álvaro
  • Arévalo, Juan C.
Ubiquitination of the TrkA neurotrophin receptor in response to NGF is critical in the regulation of TrkA activation and functions. TrkA is ubiquitinated, among other E3 ubiquitin ligases, by Nedd4-2. To understand mechanistically how TrkA ubiquitination is regulated, we performed a siRNA screening to identify deubiquitinating enzymes and found that USP36 acts as an important regulator of TrkA activation kinetics and ubiquitination. However, USP36 action on TrkA was indirect because it does not deubiquitinate TrkA. Instead, USP36 binds to Nedd4-2 and regulates the association of TrkA and Nedd4-2. In addition, depletion of USP36 increases TrkA·Nedd4-2 complex formation, whereas USP36 expression disrupts the complex, resulting in an enhancement or impairment of Nedd4-2-dependent TrkA ubiquitination, respectively. Moreover, USP36 depletion leads to enhanced total and surface TrkA expression that results in increased NGF-mediated TrkA activation and signaling that augments PC12 cell differentiation. USP36 actions extend beyond TrkA because the presence of USP36 interferes with Nedd4-2-dependent Kv7.2/3 channel regulation. Our results demonstrate that USP36 binds to and regulates the actions of Nedd4-2 over different substrates affecting their expression and functions., This work was supported by Spanish Ministry of Science and Innovation Grant BFU2008-00162, by Spanish Ministry of Economy and Competitivity Grants BFU2011-22898 and BFU2014-51846-R, and in part by FP7-PAINCAGE Integrative Project Grant Agreement 603191 (to J. C. A.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Potentiation of mitochondrial function by mitoDREADD-Gs reverses pharmacological and neurodegenerative cognitive impairment in mice

  • Pagano Zottola, Antonio C.
  • Martín-Jiménez, Rebeca
  • Lavanco, Gianluca
  • Hamel-Côté, Geneviève
  • Ramon-Duaso, Carla
  • Rodrigues, Rui S.
  • Mariani, Yamuna
  • Khan, Mehtab
  • Drago, Filippo
  • Jean, Stephanie
  • Río, Itziar Bonilla-Del
  • Jimenez-Blasco, Daniel
  • Egaña-Huguet, Jon
  • Eraso-Pichot, Abel
  • Beriain, Sandra
  • Cannich, Astrid
  • Vidal-Palencia, Laura
  • Infantino, Rosmara
  • Julio-Kalajzić, Francisca
  • Gisquet, Doriane
  • Goncalves, Ania
  • Al-Younis, Inas
  • Baussan, Yann
  • Duvezin-Caubet, Stephane
  • Devin, Anne
  • Soria-Gomez, Edgar
  • Puente, Nagore
  • Bolaños, Juan P.
  • Grandes, Pedro
  • Pouvreau, Sandrine
  • Busquets-Garcia, Arnau
  • Marsicano, Giovanni
  • Bellocchio, Luigi
  • Hebert-Chatelain, Etienne
Many brain disorders involve mitochondrial alterations, but owing to the lack of suitable tools, the causal role of mitochondrial dysfunction in pathophysiological processes is difficult to establish. Heterotrimeric guanine nucleotide-binding (G) proteins are key regulators of cell functions, and they can be found within mitochondria. Therefore, we reasoned that the activation of stimulatory mitochondrial G proteins (Gs) could rapidly promote the activity of the organelle and possibly compensate for bioenergetic dysfunction. Here, we show that a mitochondria-targeted recombinant designer receptor exclusively activated by designer drugs (mitoDREADD-Gs) can acutely trigger intramitochondrial signaling to increase mitochondrial membrane potential and oxygen consumption. In vivo activation of mitoDREADD-Gs abolished memory alterations in cannabinoid-treated mice and in two mouse models of Alzheimer's disease and frontotemporal dementia. Thus, mitoDREADD-Gs enables the establishment of causal relationships between mitochondria and biological or disease-related processes and represents an innovative potential therapeutic approach for disorders associated with mitochondrial impairment., This work was funded by the Natural Sciences and Engineering Research Council of Canada (grant number RGPIN-2015-05880 to E.H.-C.), Canadian Health Research Institute (grant number 156238 to E.H.-C. and L.B.), Canada Research Chair program (to E.H.-C.) and ResearchNB (to E.H.-C.). This work was also supported by Inserm (to G.M. and L.B.); EU–FP7 (PAINCAGE, HEALTH-603191, to G.M.); the European Research Council (Endofood, ERC–2010–StG–260515; CannaPreg, ERC-2014-PoC-640923; Micabra, ERC-2017-AdG-786467, to G.M.); Fondation pour la Recherche Medicale (DRM20101220445 to G.M.; ARF20140129235 to L.B.); the Human Frontiers Science Program (to G.M.); Region Aquitaine (to G.M.); French State/Agence Nationale de la Recherche (LABEX BRAIN ANR-10-LABX-43 and ANR-23-ce14-0004-03 to G.M., ANR-19-CE14-0039 to L.B., ERA-Net Neuron CanShank ANR-21-NEU2-0001-04 to G.M., CaMeLS ANR-23-CE16-0022-01 to G.M., Hippobese ANR-23-CE14-0004-03 to G.M.); Region Nouvelle Aquitaine (APP ESR NAq 2020 to G.M.); and the French government in the framework of the University of Bordeaux’s IdEx ‘Investments for the Future—France 2030’ program / GPR BRAIN_2030 (to G.M. and L.B.). E.S.-G. was funded by MICIU/AEI (PGC2018-093990-A-I00 and PID2021-125763NB-I00). J.P.B. was funded by MICIU/AEI (PID2022-138813OB-I00 /10.13039/501100011033 and FEDER, UE), the Instituto de Salud Carlos III (CB16/10/00282) and the European Union’s Horizon Europe research and innovation programme under MSCA Doctoral Networks 2021 (101072759, FuEl ThE bRaiN In healtThY aging and age-related diseases (ETERNITY). G.M., A.B.-G. and J.P.B. are recipients of a grant from la Caixa Foundation (agreement LCF/PR/HR23/52430016). A.B.-G., L.P-V. and C.R.D. received funding from the DIUE de la Generalitat de Catalunya (SGR 00022, 2023 FI-3 00034), from the H2020 Excellent Science—European Research Council (948217) and the Ministry of Economy and Competitiveness (RTI2018-093667-A-100; PID2021-122795OB-I00). S.P. was funded by the European Union’s Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement No. 676,144 (Synaptic Dysfunction in Alzheimer's Disease, SyDAD). Grant PID2019-107548RB-I00 funded by MICIU/AEI/10.13039/501100011033 (to P.G.); The Basque Government (grant number IT1620-22 to P.G.); and grant RD21/0009/0006 funded by Instituto de Salud Carlos III (ISCIII) and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR), ISCIII-Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS)-Red de Investigación en Atención Primaria de Adicciones (RIAPAd) (to P.G.). G.H.-C. was supported by a fellowship from New Brunswick Health Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Srivastava, Raj Kamal
  • Cutando Ruiz, Laura, 1985-
  • Ortega Alvaro, Antonio
  • Ruehle, Sabine
  • Remmers, Floortje
  • Bindila, Laura
  • Bellochio, Luigi
  • Marsicano, Giovanni
  • Lutz, Beat
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Stressful events can generate emotional memories linked to the traumatic incident, but they also can impair the formation of nonemotional memories. Although the impact of stress on emotional memories is well studied, much less is known about the influence of the emotional state on the formation of nonemotional memories. We used the novel object-recognition task as a model of nonemotional memory in mice to investigate the underlying mechanism of the deleterious effect of stress on memory consolidation. Systemic, hippocampal, and peripheral blockade of cannabinoid type-1 (CB1) receptors abolished the stress-induced memory impairment. Genetic deletion and rescue of CB1 receptors in specific cell types revealed that the CB1 receptor population specifically in dopamine β-hydroxylase (DBH)-expressing cells is both necessary and sufficient for stress-induced impairment of memory consolidation, but CB1 receptors present in other neuronal populations are not involved. Strikingly, pharmacological manipulations in mice expressing CB1 receptors exclusively in DBH(+) cells revealed that both hippocampal and peripheral receptors mediate the impact of stress on memory consolidation. Thus, CB1 receptors on adrenergic and noradrenergic cells provide previously unrecognized cross-talk between central and peripheral mechanisms in the stress-dependent regulation of nonemotional memory consolidation, suggesting new potential avenues for the treatment of cognitive aspects on stress-related disorders., We acknowledge a predoctoral fellowship from the Spanish Ministry of Education and a postdoctoral fellowship from the Investments for the Future Programme, Initiative of Excellence Bordeaux, ANR-10-IDEX-03-02 (to A.B.-G.); a postdoctoral fellowship from the Marie Curie action Seventh Framework Programme for Research and Technological Development, FP7-PEOPLE-2013 (to A.B.-G.); the partial support by FRAXA Research Foundation (M.G.-G.); a European Molecular Biology Organization postdoctoral fellowship (to L. Bellocchio); grants from Ministerio de Ciencia e Innovación [BFU2012-33500 and BFU2015-68568P (to A.O.), and SAF2014-59648-P (to R.M.) (MINECO/FEDER, UE)]; Instituto de Salud Carlos III Grant RD06/0001/0001 (to R.M.); Generalitat de Catalunya Grant SGR-2014-1547 (to R.M.); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia (R.M.); the German Research Council DFG Grants FOR926 (Core Unit Endocannabinoid Measurements) (to B.L.), CRC-TRR58 (to B.L.), and CRC1080 (to B.L.); EU-FP7 Grant REPROBESITY, HEALTH-F2-2008-223713 (to B.L. and G.M.); PainCage Grant HEALTH-2013-INNOVATION-1-603191 (to G.M.); INSERM (G.M.); European Research Council Grant ENDOFOOD, ERC–2010–StG–260515 (to G.M.); Fondation pour la Recherche Medicale (G.M.); Region Aquitaine (G.M.); and LABEX BRAIN Grant ANR-10-LABX-43 (to G.M.)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The endocannabinoid system in guarding against fear, anxiety and stress

  • Lutz, Beat
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Hillard, Cecilia J.
The endocannabinoid (eCB) system has emerged as a central integrator linking the perception of external and internal stimuli to distinct neurophysiological and behavioural outcomes (such as fear reaction, anxiety and stress-coping), thus allowing an organism to adapt to its changing environment. eCB signalling seems to determine the value of fear-evoking stimuli and to tune appropriate behavioural responses, which are essential for the organism's long-term viability, homeostasis and stress resilience; and dysregulation of eCB signalling can lead to psychiatric disorders. An understanding of the underlying neural cell populations and cellular processes enables the development of therapeutic strategies to mitigate behavioural maladaptation., B.L. was supported by the German Research Foundation (SFB TRR 58, CRC 1080 and FOR 926); G.M. by the Institut national de la santé et de la recherche médicale (INSERM), the European Commission Seventh Framework Programme (REPROBESITY, HEALTH-F2-2008-223713, PAINCAGE and HEALTH-2014-603191), the European Research Council (Endofood, ERC-2010-StG−260515, CannaPreg and ERC-2014-PoC-640923), the Fondation pour la Recherche Medicale (DRM20101220445), the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR Blanc NeuroNutriSens ANR-13-BSV4-0006 and BRAIN ANR-10-LABX-0043); R.M. by the grants SAF2014-59648P, RETICS-RTA#RD12/0028/0023, AGAUR#2014-SGR-1547 and Health-F2-2013-602891; and C.J.H. by the US National Institutes of Health grants DA038663, DA026996 and MH102838.